






Benign or Premalignant 
Skin Lesions 
.. ) 
OVERVIEW OF MEDICARE DERMATOLOGY ISSUE 
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Each fiscal year, the Health Care Financing Administration (HCFA) 
compiles Medicare Part 8 utilization statistics on a state-by-state basis. 
These statistics help a carrier understand how its allowed charges for 
a particular procedure code compares to the national average for all 
carriers. To adjust for uneven beneficiary populations, these statistics 
are compiled in terms of the total allowed amounts a carrier allowed 
for a procedure per 1 ,000 fee-for-service beneficiaries in its claim 
jurisdiction. Carriers are expected to focus their medical data analysis 
primarily on the procedures for which its allowed charges per 1,000 
beneficiaries substantially exceeded the national average. If necessary 
one or more corrective actions are initiated to resolve a utilization 
aberrancy after the completion of data analysis and medical research. 
For fiscal year 1996, HCFA provided us, and other carriers, utilization 
statistics for the first six months of 1995. This data highlighted the 
many procedure codes we allowed at a rate in excess of the national 
average during this period. -In orde-r:-to-properly -focus our resources-for 
the year, we selected 60 aberrant codes to examine further. In 
selecting the aberrancies for further study, we focused on procedures 
for which: 
• Our allowed charges per 1,000 beneficiaries were the most at 
variance with the national average; 
• Our annual allowed charges were significant; and 
• Our ability to influence/control utilization was likely. 
As a result of this analysis, procedure codes 1 7000-1 7002, the 
removal of benign or premalignant skin lesions, were among the codes 
selected for further study. Attachment 1 shows that Florida's 
utilization of these codes during the first half of 1995 was 295% 
above the national average. 
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Our analysis of utilization data and review of relevant medical liter~ture 
resulted in the following conclusions: 
Conclusions From Data Analysis 
• The aberrancy for procedure codes 1 7000-2 in Florida was 
driven primarily by dermatologists, although other specialties 
were aberrant as well. In fact, dermatologists in Florida utilized 
procedure codes 17001 and 1 7002 more than their peers in any 
other state. 
• Florida dermatologists were paid $13,436,640 for the 
destruction of benign lesions in the first 6 months of 1995. 
This represented approximately 24% of their total Medicare 
income. 
• Approximately 50% of the time, the diagnosis associated with 
the removal of a benign skin lesion in Florida was actinic 
keratosis (AK), a scaly, cutaneous lesion caused by chronic sun 
exposure. 
• The practice of treating AKs by destruction was prevalent 
throughout Florida. However, a small number of Florida 
dermatologists had a practice of removing an extraordinary 
number of AKs during a single patient encounter; for example, 
one dermatologist billed for removing approximately 200 AKs 
from a patient using a chemical peel. 
• Florida's utilization rate was 1 93 % higher than the average for 
other Sun Belt states. (See Attachment 2). 
Conclusions From Review of Medical Literature 
• Based on clinical studies about 1 to 2.4 in 1,000 AKs advance 
to squamous cell carcinoma (SCC) during a one-year period. 
• The documented metastasis rate for AK-induced SCC also 
varies, but is estimated to be between 2%-7%, substantially 
less than the metastasis rate for a SCC arising de novo. 
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• The American Academy of Dermatology's guidelines describe 
the characteristics of an AK which suggest progression to SCC 
(for example, increasing diameter or change of color). 
• Medical literature supports that lesions on certain body parts 
such as the lips, nose, ear and eyelids should be treated more 
aggressively due to their constant exposure to the elements . 
• Literature indicates that people with a history of skin cancer 
should be treated aggressively. 
• For several decades, the use of fluorouracil cream (Efudex) as a 
method to destroy A Ks has been well documented. 
• Studies on the removal of AKs for the prevention of SCC are not 
conclusive. In fact, several published physicians have 
questioned whether, based on data, treating all AKs would lead 
to a reduction in morbidity and mortality associated with SCC. 
One example is Marks, R. ( 1991): "The Role of Treatment of 
Actinic Keratoses in the Prevention of Morbidity and Mortality 
due to Squamous Cell Carcinoma," Archives of Dermatology, 
127, 1031-1033. Doctor Marks is a prominent physician who 





Based on the conclusions reached through data analysis and the 
review of medical literature, we decided to take three actions: 
• Develop a local medical review policy (LMRP) that describes 
when the removal of a benign or premalignant skin lesion would 
be considered medically necessary in order to provide a basis for 
denial in abusive situations. This policy, which was finalized in 
September 1996, is not intended to restrict the removal of AKs 
when medically indicated. Instead, it provides for removal under 
numerous conditions supported by medical literature, to include: 
There is an observable change in the AK, such as size, 
color, thickness, etc., or 
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The location of the AK is such that the probability of it 
becoming an SCC is increased (e.g., the nose, ear, and 
eyelids), or 
The history of the patient indicates some additional _risk, 
such as previous skin malignancy (including SCCs) or 
immunosuppression, or 
The patient has self-administered fluorouracil and the AKs 
have not responded to the treatment regimen. 
• Install a prepayment computer edit that requires adequate 
documentation for payment of claims for beneficiaries who have 
had more than 15 skin lesions removed in a 90-day period. This 
computer edit was installed in November 1996. Therefore, 
claims for patients who have had fewer than 1 5 lesions 
removed in approximately three months are not suspended for 
medical review. 
• Conduct a comprehensive, retrospective review for one 
dermatologist who had billed for an extraordinary number of 
skin lesion removals. This review resulted in an overpayment 
assessment of approximately $140,000, which has been 
appealed. 
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In short, the process we followed to finalize our LMRP and the related 
computer edit is the one specified by HCFA. Specifically, we: 
• Conducted extensive data analysis and medical literature 
research prior to concluding that an action was even required or 
that the appropriate action was the development of a LMRP. 
• Developed a proposed LMRP for presentation to our Carrier 
Advisory Committee (CAC), the physician panel that provides 
input on all of our proposed LMRPs. This policy was originally 
planned for presentation at the April 1996 meeting of the CAC, 
but was withdrawn to allow further dialogue with the 
dermatology representative and , through him, his society. 
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• The proposed policy was submitted at the July 1 996 meeting of 
the CAC for review and discussion. 
• A 45-day comment period commenced on July 20, 1996, the 
day of the CAC meeting. During this comment period( the 
dermatology representative on our CAC was very outspoken in 
opposition to our LMRP. We had face-to-face meetings and 
phone calls with various dermatologists and other medical 
professionals throughout and beyond the comment period. 
• Comments received were evaluated and appropriate changes 
were made to the proposed LMRP. In short, the dermatologists 
favored coverage of AK removal any time the attending 
physician deemed it appropriate and, therefore, advocated no 
policy at all. 
• The proposed LMRP was shared with Doctor Aron Primack an 
Oncologist and the Medical Officer for HCFA's Bureau of 
Program Operations. Doctor Primack agreed with our coverage 
criteria as outlined in his affidavit prepared as part of the 
dermatology litigation (see attachment 4). Additionally, we 
were advised that our policy was shared with the National 
Cancer Institute and a dermatologist on HCFA's Physician 
Advisory Committee. Neither objected to its content. 
• The LMRP was presented in final form, as approved by our 
medical directors, at the September 1996 meeting of the CAC. 
At this meeting, the dermatology representative read a letter of 
protest into the record. (See Attachment 5). Our response is 
included as attachment 6. 
• In October 1996, we released a Bulletin notifying physicians in 
Florida of our new LMRP and other LMRPs we had finalized. 
• In November 1996, after providing physicians 30 days advance 
notice, we installed a computer edit that requires adequate 
documentation for claim payment for beneficiaries who have 
had more than 1 5 skin · Iesion removals in a 90-day period. 
Suspended claims submitted with documentation are reviewed 
in accordance with our policy. Assigned claims submitted 
without any documentation are denied; unassigned claims 
submitted · without documentation result in a request to the 
physician for medical documentation. 
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• The litigation and media/public reaction to our corrective actions 
are well known and do not need to be repeated here. We would 
like, however, to address three prevalent misunderstandings: 
Misunderstanding #1: Our LMRP restricts coverage. 
.Ea.ct: There are many conditions for which the removal of 
a benign or premalignant skin lesion is medically 
necessary based on our literature research, and as 
outlined in our LMRP. These identified conditions are 
often overlooked or ignored by those who have 
challenged our policy. 
Misunderstanding #2: The use of fluorouracil cream is 
dictated by the LMRP. 
Fact: The unsuccessful use of fluorouracil cream is only 
one of many identified circumstances under which 
payment for AK removal may be made. In fact, we added 
failure of this treatment regimen to expand our policy's 
conditions of coverage. Our LMRP in no way mandates 
the use of this cream. 
Misunderstanding #3: All claims are being reviewed prior 
to payment. 
Fact: Only services that fail our computer edit are being 
reviewed to ensure compliance with our LMRP. For the 
first quarter of 1997~ this represented approximately 
8.5% of skin lesion removal services filed to Medicare 
Part B. 
• The anticipated impact of our computer edit has been sharply 
diminished by coding and pricing changes that HCFA 
implemented on January 1, 1997. With these changes HCFA 
created its own procedure codes (outside the CPT-4 procedural 
coding system) and new fees for the removal of skin lesions. 
As a result, a physician is no longer compensated additionally 
for removing more than 1 5 lesions daily. The fee for the "1 5 or 
6 
more lesions" code is capped at $224.11 per patient 
encounter. Prior to 1 997, a physician could bill separately for 
.eYfil¥ lesion removed and be compensated $228.65 for the first 
1 5 lesions plus $12.48 for each additional lesion. We believe 
that the national interest we created was, in part, respoQsible 
for this pricing/coding change. Had we been able to effectuate 
this change locally, we could have partially addressed utilization 
issues associated with the most statistically aberrant physicians 
in a more focused and straight forward manner. 
Nevertheless, for the first quarter of 1 997, the first full quarter 
our screen was operational, we experienced the following: 
As stated earlier, 8.5% of services for skin lesion removal 
failed our computer edit which resulted in medical review. 
Of these failures, 64% were denied or reduced, resulting 
in reduced payout of $182, 155 after appeals. Total 
payout was $4,286,243. 
• HCFA has been very supportive of our pos1t1on despite the 
intense interest of Congress and organized medicine in this 
matter. Secretary Shalala' s response to Congressman Shaw is 
included as an example of such support (see attachment 7). 
• In April 1 997 a national work group of Carrier Medical Directors 
finalized a "model" medical policy which very closely resembles 
our policy and includes many of our medical literature references 
including Doctor Marks' publication. This "model" policy is 
intended to serve as a guideline for all Medicare contractors and 
has already been adopted by the carriers in Mississippi and 
Rhode Island. 
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• Better anticipate and manage public reaction to our actions. 
• Construct policies in a manner that doesn't create inaccurate 
impressions or misunderstandings. For example, the initial 
placement of Efudex references in our policy caused some to 
misunderstand and misrepresent our intentions. 
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• Carefully pos1t1on our development of Medicare coverage 
guidelines within the broader context of good medical practice. 
In other words, clearly communicate that the universe of 
Medicare covered services is smaller than the universe of what 
is perceived as good medical practice. 
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